Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTDDS-GAD
- Development stage
- Discontinued
- Lead developer
- Periphagen Holdings
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
- Administration
- Intradermal
01
Overview
NTDDS-GAD (also known as NG2 GAD) is a gene therapy candidate developed using the Nerve Targeting Drug Delivery System (NTDDS) platform for the treatment of chronic pain, particularly diabetic neuropathic pain. The therapy utilizes a replication-defective herpes simplex virus (HSV) vector to deliver the gene for glutamic acid decarboxylase (GAD) to the dorsal root ganglion (DRG) neurons via intradermal injection. Once the neurons are transduced, they constitutively express GAD, which catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) from glutamate. This GABA is then released into the dorsal horn of the spinal cord, where it modulates pain transmission by acting on GABA receptors. Originally developed by Diamyd Medical, the NTDDS platform and the associated GAD programs were divested to Periphagen Holdings in 2012 while in the preclinical stage for the diabetes indication.
- Other names
- HSV-GADNG2NG-2NG 2
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on NTDDS-GAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTDDS-GAD.